Equities
Health CarePharmaceuticals & Biotechnology
  • Price (EUR)1.15
  • Today's Change0.039 / 3.47%
  • Shares traded19.29m
  • 1 Year change15.22%
  • Beta1.0902
Data delayed at least 15 minutes, as of Oct 17 2019 16:35 BST.
More ▼

Profile data is unavailable for this security.

About the company

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming’s technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals. The Company’s commercial partners are: Santarus, Sobi, MegaPharm, Eczacibasi, Transmedic and Hyupjin. The Company operates worldwide. In March 2014, it announced downsizing of the Dutch operations following from strategic re-emphasis on collaborative development efforts and out-sourcing of non-core activities.

  • Revenue in EUR (TTM)153.61m
  • Net income in EUR32.23m
  • Incorporated--
  • Employees183.00
  • Location
    Pharming Group NVDarwinweg 24LEIDEN 2333 CRNetherlandsNLD
  • Phone+31 715247400
  • Fax+31 715247445
  • Websitehttps://www.pharming.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Oncopeptides AB0.00-47.30m564.14m61.00--11.07-----10.97-10.970.009.990.00-------79.55---105.15-------------1,959.420.00-------66.03------
Guerbet SA800.60m43.44m580.63m2.85k13.531.585.760.72523.413.4162.8729.280.76161.575.46280,912.604.134.546.056.5644.2450.535.435.730.993--0.541224.62-2.1715.171.3017.974.4611.20
AddLife AB272.68m12.41m588.73m908.0045.014.4421.502.165.155.15112.9352.271.185.266.413,380,985.005.35--9.66--34.75--4.55--0.505517.800.3559--6.36--7.48------
Advanced Medical Solutions Group plc120.17m23.84m596.09m654.0025.182.8120.174.960.09510.09510.47940.85110.51462.784.92158,548.9010.2112.4310.9613.6360.4059.2819.8420.596.08106.250.049712.005.8711.5111.6914.6218.1617.08
Vectura Group PLC199.69m-90.40m617.92m453.00--1.111,066.333.09-0.1267-0.12670.280.77980.27392.924.53380,353.20-12.40---13.67--56.99---45.27--2.41--0.017--8.45---1.03------
Opus Global Nyrt372.59m60.87m643.55m3.94k5.410.94476.351.7356.3967.65345.16322.840.40176.665.3531,486,840.005.305.659.5210.2221.9033.1713.2019.510.8784--0.255---5.0028.05271.5975.46360.50--
Recipharm AB (publ)631.81m11.44m655.92m5.33k82.821.639.051.041.631.6397.1383.000.52152.715.051,005,735.000.93781.431.061.6848.6847.961.802.561.502.800.460855.8719.5424.57193.4911.0536.15--
Vetoquinol SA373.87m33.48m658.26m2.13k19.571.7713.561.762.832.8331.6131.360.80332.304.95175,358.807.157.038.698.8747.1660.048.908.641.63--0.036317.294.484.194.108.9913.535.34
DBV Technologies SA14.32m-173.81m677.21m322.00--4.47--47.30-5.80-5.800.47163.220.06550.96350.597645,447.62-79.56-47.65-97.59-53.2992.9989.91-1,214.11-1,069.772.96-96.310.1722--22.0730.60-12.45--32.32--
Pharming Group N.V.153.61m32.23m697.20m183.0023.028.9518.814.540.04820.04820.22470.12380.79351.327.42839,404.4016.65-15.9725.10-24.7884.6083.4620.98-31.001.341.440.4585--50.7881.59132.78--160.02--
Bavarian Nordic A/S84.49m-36.33m785.63m461.00--2.94--9.30-8.48-8.4819.6661.540.21662.6810.101,506,394.00-9.31-0.5336-10.68-0.680149.6667.65-42.99-1.267.52--0.1897---63.46-16.22-299.58--6.40--
Puretech Health PLC18.21m-6.61m836.86m225.00--2.62--45.96-0.0229-0.02290.05450.96620.0383--4.3269,829.10-13.04-28.57-17.99-45.76-----340.74-865.69----0.2374--718.4619.53-264.91--50.17--
Data as of Oct 17 2019. Currency figures normalised to Pharming Group NV's reporting currency: Euro EUR

Institutional shareholders

10.13%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co.as of 31 Aug 201919.51m3.14%
Polar Capital LLPas of 25 Apr 201818.50m2.98%
DWS Investments (UK) Ltd.as of 03 Oct 20198.32m1.34%
BlackRock Fund Advisorsas of 03 Oct 20197.14m1.15%
Norges Bank Investment Managementas of 31 Dec 20185.53m0.89%
TIAA-CREF Investment Management LLCas of 31 Aug 20191.15m0.18%
BlackRock Advisors (UK) Ltd.as of 03 Oct 2019968.98k0.16%
SEI Investments Management Corp.as of 31 Aug 2019609.14k0.10%
Philippe Hottinguer & Cie Gestion SASas of 30 Jun 2019600.00k0.10%
Principal Global Investors LLCas of 30 Apr 2019599.56k0.10%
More ▼
Data from 31 Dec 2018 - 30 Jun 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.